Canaccord Genuity Maintains Buy on Tenaya Therapeutics, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has reiterated its Buy rating for Tenaya Therapeutics, maintaining a price target of $16.
October 18, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity has reiterated its Buy rating for Tenaya Therapeutics, maintaining a price target of $16.
The reaffirmation of a Buy rating and a specific price target by Canaccord Genuity is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100